These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38922940)

  • 1. Letter: Persisting with persistence-A caution as an outcome measure in inflammatory bowel disease: Authors' reply.
    Yiu TH; Ko Y; Pudipeddi A; Natale P; Leong RW
    Aliment Pharmacol Ther; 2024 Aug; 60(3):427-428. PubMed ID: 38922940
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: Persisting with persistence-A caution as an outcome measure in inflammatory bowel disease.
    Rao V; Chen G; Koh E; Segal JP
    Aliment Pharmacol Ther; 2024 Aug; 60(3):425-426. PubMed ID: 38923034
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter: infliximab therapy for patients with inflammatory bowel disease--some unanswered questions. Authors' reply.
    Buurman DJ; Maurer JM; Keizer RJ; Kosterink JG; Dijkstra G
    Aliment Pharmacol Ther; 2015 Nov; 42(9):1134. PubMed ID: 26427756
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial: Treatments for inflammatory bowel disease across age-spectrum-Are they the same? Authors' reply.
    Wewer MD; Nordestgaard RLM; Malham M; Wewer V; Boysen T; Burisch J
    Aliment Pharmacol Ther; 2024 Aug; 60(4):525-526. PubMed ID: 38978270
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter: rapid infliximab infusion is not always safe--authors' reply.
    Neef H; Adler J
    Aliment Pharmacol Ther; 2013 Oct; 38(7):844-5. PubMed ID: 24001100
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter: infliximab therapy for patients with inflammatory bowel disease--some unanswered questions.
    Srinivas NR
    Aliment Pharmacol Ther; 2015 Nov; 42(9):1133. PubMed ID: 26427755
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of the drug treatment regimens for inflammatory bowel disease.
    Brock EM; Zabihollah M
    Expert Opin Pharmacother; 1999 Nov; 1(1):15-8. PubMed ID: 11249558
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in patients with inflammatory bowel disease.
    Richard N; Vuitton L; Fumery M
    Aliment Pharmacol Ther; 2023 Mar; 57(6):741-742. PubMed ID: 36821749
    [No Abstract]   [Full Text] [Related]  

  • 9. Letter: Recommendations for the management of latent tuberculosis infection in IBD patients may not be applicable in all settings--author's reply.
    Papay P; Winkler S; Reinisch W
    Aliment Pharmacol Ther; 2013 Feb; 37(3):367-8. PubMed ID: 23281727
    [No Abstract]   [Full Text] [Related]  

  • 10. ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.
    Danese S; Fiorino G; Raine T; Ferrante M; Kemp K; Kierkus J; Lakatos PL; Mantzaris G; van der Woude J; Panes J; Peyrin-Biroulet L
    J Crohns Colitis; 2017 Jan; 11(1):26-34. PubMed ID: 27927718
    [No Abstract]   [Full Text] [Related]  

  • 11. Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation.
    Indriolo A; Fagiuoli S; Pasulo L; Fiorino G; Danese S; Ravelli P
    Aliment Pharmacol Ther; 2013 Apr; 37(8):840-2. PubMed ID: 23496317
    [No Abstract]   [Full Text] [Related]  

  • 12. [Biological drugs in inflammatory bowel disease: Management and care].
    Guerra I; Bermejo F
    Rev Esp Enferm Dig; 2015 Jul; 107(7):454. PubMed ID: 26140643
    [No Abstract]   [Full Text] [Related]  

  • 13. Response to letter to the editor.
    Bressler B; Devlin S; Bernstein C; Singh H; Fedorak R
    Can J Gastroenterol Hepatol; 2014 Sep; 28(8):453-4. PubMed ID: 25229468
    [No Abstract]   [Full Text] [Related]  

  • 14. Letter to the Editor: Feasibility and Efficiency of an E-Health Preadmission Assessment System for Intravenous Therapy in Inflammatory Bowel Disease.
    Pouillon L; Hoefkens E; Verheyen V; Bronswijk M; Van Olmen A; Van Dessel S; Siborgs N; Bossuyt P
    Inflamm Bowel Dis; 2020 Jan; 26(2):e11-e12. PubMed ID: 31793628
    [No Abstract]   [Full Text] [Related]  

  • 15. Letter: dermatological complications with therapy for inflammatory bowel disease--authors' reply.
    Ghosh S; Moran GW
    Aliment Pharmacol Ther; 2014 Jan; 39(2):233-4. PubMed ID: 24330245
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Patient Guide.
    American Gastroenterological Association
    Gastroenterology; 2017 Sep; 153(3):860-861. PubMed ID: 28774545
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of biologics in inflammatory bowel disease patients with cirrhosis.
    Dhere T
    Inflamm Bowel Dis; 2011 Feb; 17(2):E15-6. PubMed ID: 20878757
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter: the effect of anti-COVID-19 treatment on the outcome of patients with inflammatory bowel disease-authors' reply.
    Hadi Y; Kochhar GS
    Aliment Pharmacol Ther; 2022 Jul; 56(1):179. PubMed ID: 35689310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Clinical Decision Support Tool.
    American Gastroenterological Association
    Gastroenterology; 2017 Sep; 153(3):858-859. PubMed ID: 28778399
    [No Abstract]   [Full Text] [Related]  

  • 20. Disease-modifying anti-inflammatory bowel disease drugs (DMAIDs): the missing term in the literature.
    Peyrin-Biroulet L
    Am J Gastroenterol; 2013 May; 108(5):859-60. PubMed ID: 23644972
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.